Loading...

Brilliant Violet 421™ anti-mouse F4/80 Antibody Brilliant Violet 421™ anti-mouse F4/80 Antibody

Pricing & Availability
Clone
BM8 (See other available formats)
Regulatory Status
RUO
Other Names
EMR1, Ly71
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_BM8_BV421_F4slash80_Antibody_1_FC_060616
Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with F4/80 (clone BM8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 1_BM8_BV421_F4slash80_Antibody_1_FC_060616
    Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with F4/80 (clone BM8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 2_BM8_BV421_F4slash80_Antibody_2_IHCF_060616
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS plus 5% rat/mouse serum for 30 minutes at room temperature. Then the section was stained with 2 µg/ml of anti-mouse F4/80 (clone BM8) Brilliant Violet 421™ (Blue) and anti-mouse CD8a (clone 53-6.7) Alexa Fluor® 647 (red) overnight at 4°C. The image was captured with a 10X objective.
  • 34_Mouse_Spleen_F480_MHCII
    Confocal image of C57BL/6 mouse spleen sample acquired using the IBEX method of highly multiplexed antibody-based imaging: MHCII (blue) in Cycle 2 and F4/80 (magenta) in Cycle 2. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 59_Mouse_Lymph_Node_F480_CD68_NK1.1
    Mice were injected subcutaneously with sheep red blood cells in a volume of 25 µl per site on days 0 and 4 and harvested on day 11. Confocal image of C57BL/6 mouse lymph node acquired using the IBEX method of highly multiplexed antibody-based imaging: F4/80 (cyan) in Cycle 3, CD68 (blue) in Cycle 6, and NK1.1 (magenta) in Cycle 9. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Brilliant Violet 421™ spectral data See high resolution IHC data...
Cat # Size Price Quantity Check Availability Save
123131 125 µL DKK1212
Check Availability


Need larger quantities of this item?
Request Bulk Quote
123137 50 µg DKK1503
Check Availability


Need larger quantities of this item?
Request Bulk Quote
123132 500 µL DKK2353
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

F4/80, also known as EMR1 or Ly71, is a 160 kD glycoprotein of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80 has been widely used as a murine macrophage marker. It is expressed on a majority of tissue macrophages, including macrophages in the lung, gut, peritoneal cavity, thymus, and red pulp of the spleen, Kupffer cells, Langerhans cells, microglia, and certain dendritic cells. It is not expressed on macrophages located in the T cell areas of the spleen, lymph node, or Peyer's patch. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for the induction of CD8+ T cells-mediated peripheral tolerance.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Murine macrophages
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemical staining on frozen tissue sections, the suggested use of this reagent is 2.0 µg/ml. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections1,2 and formalin-fixed paraffin-embedded sections6,7, Western blotting, and spatial biology (IBEX)12,13.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References
  1. Schaller E, et al. 2002. Mol. Cell. Biol. 22:8035. (IHC)
  2. Stevceva L, et al. 2001. BMC Clin Pathol. 1:3. (IHC)
  3. Kobayashi M, et al.2008. J. Leukoc. Biol. 83:1354. PubMed
  4. Poeckel D, et al. 2009. J. Biol Chem. 284:21077. PubMed
  5. Glass AM, et al. 2013. J. Immunol. 190:4830. PubMed
  6. Koehm S, et al. 2007. J. Allergy Clin. Immunol. 120:570. (IHC)
  7. Rankin AL, et al. 2010. J. Immunol. 184:1526. (IHC)
  8. Sasi SP, et al. 2014. J Biol Chem. 289:14178. PubMed
  9. Thakus VS, et al. 2014. Toxicol Lett. 230:322. PubMed
  10. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
  11. Hirakawa H, et al. 2015. PLoS One. 10:119360. PubMed
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  2. Wang L, et al. 2022. Cell Metab. 34:75. PubMed
  3. Zhang Y, et al. 2022. J Cereb Blood Flow Metab. 42:952. PubMed
  4. Kang H, et al. 2022. Adv Mater. 34:e2106500. PubMed
  5. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  6. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  7. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  8. Lu Z, et al. 2022. Cell Rep. 41:111482. PubMed
  9. Siret C, et al. 2022. Nat Commun. 13:7366. PubMed
  10. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  11. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  12. Taniguchi S, et al. 2023. Nat Commun. 14:143. PubMed
  13. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  14. Yang L, et al. 2023. Sci Rep. 13:1827. PubMed
  15. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
  16. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  17. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  18. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  19. Wu Q, et al. 2023. Front Immunol. 13:1081719. PubMed
  20. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  21. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  22. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  23. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  24. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  25. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  26. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  27. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  28. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  29. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  30. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  31. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  32. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  33. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  34. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  35. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  36. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  37. Feng J, et al. 2021. iScience. 24:103004. PubMed
  38. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  39. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  40. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  41. Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed
  42. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  43. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  44. Nakamoto N, et al. 2019. Nat Microbiol. 4:492. PubMed
  45. Iturri L, et al. 2021. Immunity. . PubMed
  46. Sun K, et al. 2016. J Exp Med. 213: 1851 - 1864. PubMed
  47. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  48. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  49. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  50. Laumonnier Y, et al. 2020. Curr Protoc Immunol. 130:e100. PubMed
  51. Croasdell A, et al. 2016. J Immunol. 196: 2742 - 2752. PubMed
  52. Karsten C, et al. 2015. J Immunol. 194:1841. PubMed
  53. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  54. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  55. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  56. Müller P, et al. 2015. Sci Transl Med. 7: 315ra188. PubMed
  57. Glass A, et al. 2013. J Immunol. 190:4830. PubMed
  58. Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed
  59. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  60. Du W, et al. 2021. Mol Cancer Res. 19:1412. PubMed
  61. Opzoomer JW, et al. 2021. Sci Adv. 7:eabg9518. PubMed
  62. Paterson N, et al. 2022. Elife. 11:. PubMed
  63. Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed
  64. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  65. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  66. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  67. Eggold JT, et al. 2022. Mol Cancer Ther. 21:371. PubMed
  68. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  69. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  70. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
  71. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  72. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  73. Chi A, et al. 2022. Front Endocrinol (Lausanne). 13:871548. PubMed
  74. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  75. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  76. Li J, et al. 2020. Elife. 9:00. PubMed
  77. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
  78. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  79. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  80. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  81. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  82. Cao DY, et al. 2020. J Biol Chem. 295:1369. PubMed
  83. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  84. He J, et al. 2019. J Clin Invest. 130. PubMed
  85. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  86. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  87. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  88. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  89. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  90. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Troutman TD, et al. 2021. STAR Protocols. 2(1):100363. PubMed
  92. McDonald LT, et al. 2018. Am J Physiol Heart Circ Physiol. 315:H92. PubMed
  93. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  94. Babagana M, et al. 2021. Aging (Albany NY). 13:19207. PubMed
  95. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  96. Lim J et al. 2019. Elife. 8 pii: e44452. PubMed
  97. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  98. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
  99. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  100. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  101. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  102. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  103. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  104. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  105. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  106. Ledo JH, et al. 2020. PLoS One. e0237773:15. PubMed
  107. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  108. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  109. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  110. Heinen A, et al. 2019. Mol Ther. 27:46:00. PubMed
  111. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  112. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  113. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  114. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  115. Liao X, et al. 2022. JCI Insight. 7:. PubMed
  116. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  117. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  118. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  119. Fan HH, et al. 2021. Methods Mol Biol. 2276:203. PubMed
  120. Zhang Y, et al. 2021. JCI Insight. 6:e150735. PubMed
  121. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  122. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  123. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  124. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  125. Schuster EM, et al. 2022. Nat Metab. 4:856. PubMed
  126. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  127. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  128. Shan Z, et al. 2021. eLife. 10:00. PubMed
  129. Ying L, et al. 2021. Front Cell Dev Biol. 9:672032. PubMed
  130. Cai W, et al. 2019. J Neuroinflammation. 0.788194444. PubMed
  131. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  132. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  133. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  134. Yao W, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.07.014. PubMed
  135. Ledo JH, et al. 2020. Mol Psychiatry. . PubMed
  136. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  137. Wang L, et al. 2022. Cell Metab. 34:75. PubMed
  138. Zhang Y, et al. 2022. J Cereb Blood Flow Metab. 42:952. PubMed
  139. Kang H, et al. 2022. Adv Mater. 34:e2106500. PubMed
  140. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  141. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  142. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  143. Lu Z, et al. 2022. Cell Rep. 41:111482. PubMed
  144. Siret C, et al. 2022. Nat Commun. 13:7366. PubMed
  145. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  146. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  147. Taniguchi S, et al. 2023. Nat Commun. 14:143. PubMed
  148. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  149. Yang L, et al. 2023. Sci Rep. 13:1827. PubMed
  150. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
  151. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  152. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  153. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  154. Wu Q, et al. 2023. Front Immunol. 13:1081719. PubMed
  155. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  156. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  157. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  158. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  159. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  160. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  161. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  162. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  163. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  164. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  165. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  166. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  167. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  168. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  169. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  170. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  171. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  172. Feng J, et al. 2021. iScience. 24:103004. PubMed
  173. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  174. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  175. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  176. Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed
  177. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  178. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  179. Nakamoto N, et al. 2019. Nat Microbiol. 4:492. PubMed
  180. Iturri L, et al. 2021. Immunity. . PubMed
  181. Sun K, et al. 2016. J Exp Med. 213: 1851 - 1864. PubMed
  182. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  183. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  184. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  185. Laumonnier Y, et al. 2020. Curr Protoc Immunol. 130:e100. PubMed
  186. Croasdell A, et al. 2016. J Immunol. 196: 2742 - 2752. PubMed
  187. Karsten C, et al. 2015. J Immunol. 194:1841. PubMed
  188. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  189. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  190. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  191. Müller P, et al. 2015. Sci Transl Med. 7: 315ra188. PubMed
  192. Glass A, et al. 2013. J Immunol. 190:4830. PubMed
  193. Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed
  194. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  195. Du W, et al. 2021. Mol Cancer Res. 19:1412. PubMed
  196. Opzoomer JW, et al. 2021. Sci Adv. 7:eabg9518. PubMed
  197. Paterson N, et al. 2022. Elife. 11:. PubMed
  198. Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed
  199. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  200. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  201. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  202. Eggold JT, et al. 2022. Mol Cancer Ther. 21:371. PubMed
  203. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  204. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  205. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
  206. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  207. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  208. Chi A, et al. 2022. Front Endocrinol (Lausanne). 13:871548. PubMed
  209. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  210. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  211. Li J, et al. 2020. Elife. 9:00. PubMed
  212. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
  213. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  214. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  215. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  216. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  217. Cao DY, et al. 2020. J Biol Chem. 295:1369. PubMed
  218. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  219. He J, et al. 2019. J Clin Invest. 130. PubMed
  220. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  221. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  222. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  223. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  224. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  225. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  226. Troutman TD, et al. 2021. STAR Protocols. 2(1):100363. PubMed
  227. McDonald LT, et al. 2018. Am J Physiol Heart Circ Physiol. 315:H92. PubMed
  228. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  229. Babagana M, et al. 2021. Aging (Albany NY). 13:19207. PubMed
  230. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  231. Lim J et al. 2019. Elife. 8 pii: e44452. PubMed
  232. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  233. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
  234. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  235. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  236. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  237. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  238. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  239. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  240. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  241. Ledo JH, et al. 2020. PLoS One. e0237773:15. PubMed
  242. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  243. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  244. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  245. Heinen A, et al. 2019. Mol Ther. 27:46:00. PubMed
  246. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  247. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  248. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  249. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  250. Liao X, et al. 2022. JCI Insight. 7:. PubMed
  251. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  252. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  253. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  254. Fan HH, et al. 2021. Methods Mol Biol. 2276:203. PubMed
  255. Zhang Y, et al. 2021. JCI Insight. 6:e150735. PubMed
  256. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  257. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  258. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  259. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  260. Schuster EM, et al. 2022. Nat Metab. 4:856. PubMed
  261. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  262. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  263. Shan Z, et al. 2021. eLife. 10:00. PubMed
  264. Ying L, et al. 2021. Front Cell Dev Biol. 9:672032. PubMed
  265. Cai W, et al. 2019. J Neuroinflammation. 0.788194444. PubMed
  266. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  267. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  268. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  269. Yao W, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.07.014. PubMed
  270. Ledo JH, et al. 2020. Mol Psychiatry. . PubMed
RRID
AB_10901171 (BioLegend Cat. No. 123131)
AB_2563102 (BioLegend Cat. No. 123137)
AB_11203717 (BioLegend Cat. No. 123132)

Antigen Details

Structure
EGF-TM7 family member, 160 kD glycoprotein
Distribution

Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kupffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells

Function
Induction of immunological tolerance
Cell Type
Dendritic cells, Langerhans cells, Macrophages, Tregs
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Antigen References

1. Austy JM and Gordon S. 1981. Eur. J. Immunol. 11:805.
2. Hume DA, et al. 1983. J. Exp. Med. 158:1522.
3. Ruedl C, et al. 1996. Eur. J. Immunol. 26:1801.
4. McKnight AJ, et al. 1996. J. Biol. Chem. 271:486.
5. Lin HH, et al. 2005. J. Exp. Med. 201:1615.

Gene ID
13733 View all products for this Gene ID
UniProt
View information about F4/80 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All F4/80 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 605™ anti-mouse F4/80 BM8 FC
Purified anti-mouse F4/80 BM8 FC,IHC,WB
Biotin anti-mouse F4/80 BM8 FC,IHC
FITC anti-mouse F4/80 BM8 FC
PE anti-mouse F4/80 BM8 FC
PE/Cyanine5 anti-mouse F4/80 BM8 FC
PE/Cyanine7 anti-mouse F4/80 BM8 FC
APC anti-mouse F4/80 BM8 FC
APC/Cyanine7 anti-mouse F4/80 BM8 FC
Alexa Fluor® 488 anti-mouse F4/80 BM8 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse F4/80 BM8 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse F4/80 BM8 FC
PerCP anti-mouse F4/80 BM8 FC
PerCP/Cyanine5.5 anti-mouse F4/80 BM8 FC
Alexa Fluor® 700 anti-mouse F4/80 BM8 FC
Brilliant Violet 421™ anti-mouse F4/80 BM8 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse F4/80 BM8 FC
Alexa Fluor® 594 anti-mouse F4/80 BM8 IHC-F
Brilliant Violet 785™ anti-mouse F4/80 BM8 FC
Purified anti-mouse F4/80 (Maxpar® Ready) BM8 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse F4/80 BM8 FC
Brilliant Violet 650™ anti-mouse F4/80 BM8 FC
Brilliant Violet 711™ anti-mouse F4/80 BM8 FC
APC/Fire™ 750 anti-mouse F4/80 BM8 FC
TotalSeq™-A0114 anti-mouse F4/80 BM8 PG
TotalSeq™-B0114 anti-mouse F4/80 BM8 PG
TotalSeq™-C0114 anti-mouse F4/80 BM8 PG
Spark YG™ 570 anti-mouse F4/80 BM8 IHC-F
KIRAVIA Blue 520™ anti-mouse F4/80 BM8 FC
Ultra-LEAF™ Purified anti-mouse F4/80 BM8 FC,IHC,WB
APC/Fire™ 810 anti-mouse F4/80 BM8 FC
Spark NIR™ 685 anti-mouse F4/80 BM8 FC
Spark Blue™ 550 anti-mouse F4/80 BM8 FC
Brilliant Violet 570™ anti-mouse F4/80 BM8 FC
Brilliant Violet 750™ anti-mouse F4/80 BM8 FC
PE/Fire™ 810 anti-mouse F4/80 BM8 FC
Spark Red™ 718 anti-mouse F4/80 (Flexi-Fluor™) BM8 FC
Spark Blue™ 574 anti-mouse F4/80 (Flexi-Fluor™) BM8 FC
PE/Fire™ 640 anti-mouse F4/80 BM8 FC
PerCP/Fire™ 806 anti-mouse F4/80 BM8 FC
Go To Top Version: 4    Revision Date: 04/20/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
BM8 (See other available formats)
Regulatory Status
RUO
Other Names
EMR1, Ly71
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_BM8_BV421_F4slash80_Antibody_1_FC_060616
Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with F4/80 (clone BM8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 1_BM8_BV421_F4slash80_Antibody_1_FC_060616
    Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with F4/80 (clone BM8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 2_BM8_BV421_F4slash80_Antibody_2_IHCF_060616
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS plus 5% rat/mouse serum for 30 minutes at room temperature. Then the section was stained with 2 µg/ml of anti-mouse F4/80 (clone BM8) Brilliant Violet 421™ (Blue) and anti-mouse CD8a (clone 53-6.7) Alexa Fluor® 647 (red) overnight at 4°C. The image was captured with a 10X objective.
  • 34_Mouse_Spleen_F480_MHCII
    Confocal image of C57BL/6 mouse spleen sample acquired using the IBEX method of highly multiplexed antibody-based imaging: MHCII (blue) in Cycle 2 and F4/80 (magenta) in Cycle 2. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 59_Mouse_Lymph_Node_F480_CD68_NK1.1
    Mice were injected subcutaneously with sheep red blood cells in a volume of 25 µl per site on days 0 and 4 and harvested on day 11. Confocal image of C57BL/6 mouse lymph node acquired using the IBEX method of highly multiplexed antibody-based imaging: F4/80 (cyan) in Cycle 3, CD68 (blue) in Cycle 6, and NK1.1 (magenta) in Cycle 9. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Brilliant Violet 421™ spectral data See high resolution IHC data...
Cat # Size Price Quantity Check Availability Save
123131 125 µL DKK1212
Check Availability


Need larger quantities of this item?
Request Bulk Quote
123137 50 µg DKK1503
Check Availability


Need larger quantities of this item?
Request Bulk Quote
123132 500 µL DKK2353
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

F4/80, also known as EMR1 or Ly71, is a 160 kD glycoprotein of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80 has been widely used as a murine macrophage marker. It is expressed on a majority of tissue macrophages, including macrophages in the lung, gut, peritoneal cavity, thymus, and red pulp of the spleen, Kupffer cells, Langerhans cells, microglia, and certain dendritic cells. It is not expressed on macrophages located in the T cell areas of the spleen, lymph node, or Peyer's patch. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for the induction of CD8+ T cells-mediated peripheral tolerance.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Murine macrophages
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemical staining on frozen tissue sections, the suggested use of this reagent is 2.0 µg/ml. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections1,2 and formalin-fixed paraffin-embedded sections6,7, Western blotting, and spatial biology (IBEX)12,13.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References
  1. Schaller E, et al. 2002. Mol. Cell. Biol. 22:8035. (IHC)
  2. Stevceva L, et al. 2001. BMC Clin Pathol. 1:3. (IHC)
  3. Kobayashi M, et al.2008. J. Leukoc. Biol. 83:1354. PubMed
  4. Poeckel D, et al. 2009. J. Biol Chem. 284:21077. PubMed
  5. Glass AM, et al. 2013. J. Immunol. 190:4830. PubMed
  6. Koehm S, et al. 2007. J. Allergy Clin. Immunol. 120:570. (IHC)
  7. Rankin AL, et al. 2010. J. Immunol. 184:1526. (IHC)
  8. Sasi SP, et al. 2014. J Biol Chem. 289:14178. PubMed
  9. Thakus VS, et al. 2014. Toxicol Lett. 230:322. PubMed
  10. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
  11. Hirakawa H, et al. 2015. PLoS One. 10:119360. PubMed
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  2. Wang L, et al. 2022. Cell Metab. 34:75. PubMed
  3. Zhang Y, et al. 2022. J Cereb Blood Flow Metab. 42:952. PubMed
  4. Kang H, et al. 2022. Adv Mater. 34:e2106500. PubMed
  5. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  6. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  7. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  8. Lu Z, et al. 2022. Cell Rep. 41:111482. PubMed
  9. Siret C, et al. 2022. Nat Commun. 13:7366. PubMed
  10. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  11. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  12. Taniguchi S, et al. 2023. Nat Commun. 14:143. PubMed
  13. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  14. Yang L, et al. 2023. Sci Rep. 13:1827. PubMed
  15. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
  16. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  17. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  18. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  19. Wu Q, et al. 2023. Front Immunol. 13:1081719. PubMed
  20. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  21. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  22. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  23. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  24. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  25. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  26. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  27. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  28. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  29. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  30. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  31. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  32. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  33. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  34. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  35. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  36. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  37. Feng J, et al. 2021. iScience. 24:103004. PubMed
  38. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  39. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  40. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  41. Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed
  42. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  43. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  44. Nakamoto N, et al. 2019. Nat Microbiol. 4:492. PubMed
  45. Iturri L, et al. 2021. Immunity. . PubMed
  46. Sun K, et al. 2016. J Exp Med. 213: 1851 - 1864. PubMed
  47. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  48. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  49. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  50. Laumonnier Y, et al. 2020. Curr Protoc Immunol. 130:e100. PubMed
  51. Croasdell A, et al. 2016. J Immunol. 196: 2742 - 2752. PubMed
  52. Karsten C, et al. 2015. J Immunol. 194:1841. PubMed
  53. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  54. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  55. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  56. Müller P, et al. 2015. Sci Transl Med. 7: 315ra188. PubMed
  57. Glass A, et al. 2013. J Immunol. 190:4830. PubMed
  58. Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed
  59. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  60. Du W, et al. 2021. Mol Cancer Res. 19:1412. PubMed
  61. Opzoomer JW, et al. 2021. Sci Adv. 7:eabg9518. PubMed
  62. Paterson N, et al. 2022. Elife. 11:. PubMed
  63. Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed
  64. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  65. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  66. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  67. Eggold JT, et al. 2022. Mol Cancer Ther. 21:371. PubMed
  68. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  69. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  70. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
  71. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  72. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  73. Chi A, et al. 2022. Front Endocrinol (Lausanne). 13:871548. PubMed
  74. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  75. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  76. Li J, et al. 2020. Elife. 9:00. PubMed
  77. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
  78. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  79. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  80. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  81. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  82. Cao DY, et al. 2020. J Biol Chem. 295:1369. PubMed
  83. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  84. He J, et al. 2019. J Clin Invest. 130. PubMed
  85. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  86. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  87. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  88. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  89. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  90. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Troutman TD, et al. 2021. STAR Protocols. 2(1):100363. PubMed
  92. McDonald LT, et al. 2018. Am J Physiol Heart Circ Physiol. 315:H92. PubMed
  93. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  94. Babagana M, et al. 2021. Aging (Albany NY). 13:19207. PubMed
  95. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  96. Lim J et al. 2019. Elife. 8 pii: e44452. PubMed
  97. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  98. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
  99. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  100. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  101. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  102. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  103. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  104. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  105. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  106. Ledo JH, et al. 2020. PLoS One. e0237773:15. PubMed
  107. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  108. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  109. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  110. Heinen A, et al. 2019. Mol Ther. 27:46:00. PubMed
  111. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  112. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  113. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  114. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  115. Liao X, et al. 2022. JCI Insight. 7:. PubMed
  116. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  117. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  118. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  119. Fan HH, et al. 2021. Methods Mol Biol. 2276:203. PubMed
  120. Zhang Y, et al. 2021. JCI Insight. 6:e150735. PubMed
  121. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  122. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  123. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  124. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  125. Schuster EM, et al. 2022. Nat Metab. 4:856. PubMed
  126. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  127. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  128. Shan Z, et al. 2021. eLife. 10:00. PubMed
  129. Ying L, et al. 2021. Front Cell Dev Biol. 9:672032. PubMed
  130. Cai W, et al. 2019. J Neuroinflammation. 0.788194444. PubMed
  131. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  132. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  133. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  134. Yao W, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.07.014. PubMed
  135. Ledo JH, et al. 2020. Mol Psychiatry. . PubMed
  136. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  137. Wang L, et al. 2022. Cell Metab. 34:75. PubMed
  138. Zhang Y, et al. 2022. J Cereb Blood Flow Metab. 42:952. PubMed
  139. Kang H, et al. 2022. Adv Mater. 34:e2106500. PubMed
  140. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  141. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  142. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  143. Lu Z, et al. 2022. Cell Rep. 41:111482. PubMed
  144. Siret C, et al. 2022. Nat Commun. 13:7366. PubMed
  145. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  146. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  147. Taniguchi S, et al. 2023. Nat Commun. 14:143. PubMed
  148. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  149. Yang L, et al. 2023. Sci Rep. 13:1827. PubMed
  150. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
  151. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  152. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  153. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  154. Wu Q, et al. 2023. Front Immunol. 13:1081719. PubMed
  155. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  156. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  157. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  158. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  159. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  160. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  161. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  162. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  163. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  164. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  165. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  166. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  167. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  168. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  169. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  170. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  171. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  172. Feng J, et al. 2021. iScience. 24:103004. PubMed
  173. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  174. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  175. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  176. Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed
  177. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  178. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  179. Nakamoto N, et al. 2019. Nat Microbiol. 4:492. PubMed
  180. Iturri L, et al. 2021. Immunity. . PubMed
  181. Sun K, et al. 2016. J Exp Med. 213: 1851 - 1864. PubMed
  182. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  183. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  184. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  185. Laumonnier Y, et al. 2020. Curr Protoc Immunol. 130:e100. PubMed
  186. Croasdell A, et al. 2016. J Immunol. 196: 2742 - 2752. PubMed
  187. Karsten C, et al. 2015. J Immunol. 194:1841. PubMed
  188. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  189. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  190. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  191. Müller P, et al. 2015. Sci Transl Med. 7: 315ra188. PubMed
  192. Glass A, et al. 2013. J Immunol. 190:4830. PubMed
  193. Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed
  194. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  195. Du W, et al. 2021. Mol Cancer Res. 19:1412. PubMed
  196. Opzoomer JW, et al. 2021. Sci Adv. 7:eabg9518. PubMed
  197. Paterson N, et al. 2022. Elife. 11:. PubMed
  198. Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed
  199. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  200. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  201. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  202. Eggold JT, et al. 2022. Mol Cancer Ther. 21:371. PubMed
  203. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  204. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  205. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
  206. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  207. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  208. Chi A, et al. 2022. Front Endocrinol (Lausanne). 13:871548. PubMed
  209. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  210. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  211. Li J, et al. 2020. Elife. 9:00. PubMed
  212. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
  213. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  214. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  215. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  216. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  217. Cao DY, et al. 2020. J Biol Chem. 295:1369. PubMed
  218. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  219. He J, et al. 2019. J Clin Invest. 130. PubMed
  220. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  221. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  222. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  223. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  224. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  225. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  226. Troutman TD, et al. 2021. STAR Protocols. 2(1):100363. PubMed
  227. McDonald LT, et al. 2018. Am J Physiol Heart Circ Physiol. 315:H92. PubMed
  228. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  229. Babagana M, et al. 2021. Aging (Albany NY). 13:19207. PubMed
  230. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  231. Lim J et al. 2019. Elife. 8 pii: e44452. PubMed
  232. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  233. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
  234. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  235. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  236. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  237. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  238. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  239. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  240. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  241. Ledo JH, et al. 2020. PLoS One. e0237773:15. PubMed
  242. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  243. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  244. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  245. Heinen A, et al. 2019. Mol Ther. 27:46:00. PubMed
  246. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  247. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  248. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  249. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  250. Liao X, et al. 2022. JCI Insight. 7:. PubMed
  251. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  252. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  253. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  254. Fan HH, et al. 2021. Methods Mol Biol. 2276:203. PubMed
  255. Zhang Y, et al. 2021. JCI Insight. 6:e150735. PubMed
  256. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  257. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  258. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  259. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  260. Schuster EM, et al. 2022. Nat Metab. 4:856. PubMed
  261. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  262. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  263. Shan Z, et al. 2021. eLife. 10:00. PubMed
  264. Ying L, et al. 2021. Front Cell Dev Biol. 9:672032. PubMed
  265. Cai W, et al. 2019. J Neuroinflammation. 0.788194444. PubMed
  266. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  267. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  268. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  269. Yao W, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.07.014. PubMed
  270. Ledo JH, et al. 2020. Mol Psychiatry. . PubMed
RRID
AB_10901171 (BioLegend Cat. No. 123131)
AB_2563102 (BioLegend Cat. No. 123137)
AB_11203717 (BioLegend Cat. No. 123132)

Antigen Details

Structure
EGF-TM7 family member, 160 kD glycoprotein
Distribution

Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kupffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells

Function
Induction of immunological tolerance
Cell Type
Dendritic cells, Langerhans cells, Macrophages, Tregs
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Antigen References

1. Austy JM and Gordon S. 1981. Eur. J. Immunol. 11:805.
2. Hume DA, et al. 1983. J. Exp. Med. 158:1522.
3. Ruedl C, et al. 1996. Eur. J. Immunol. 26:1801.
4. McKnight AJ, et al. 1996. J. Biol. Chem. 271:486.
5. Lin HH, et al. 2005. J. Exp. Med. 201:1615.

Gene ID
13733 View all products for this Gene ID
UniProt
View information about F4/80 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All F4/80 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 605™ anti-mouse F4/80 BM8 FC
Purified anti-mouse F4/80 BM8 FC,IHC,WB
Biotin anti-mouse F4/80 BM8 FC,IHC
FITC anti-mouse F4/80 BM8 FC
PE anti-mouse F4/80 BM8 FC
PE/Cyanine5 anti-mouse F4/80 BM8 FC
PE/Cyanine7 anti-mouse F4/80 BM8 FC
APC anti-mouse F4/80 BM8 FC
APC/Cyanine7 anti-mouse F4/80 BM8 FC
Alexa Fluor® 488 anti-mouse F4/80 BM8 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse F4/80 BM8 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse F4/80 BM8 FC
PerCP anti-mouse F4/80 BM8 FC
PerCP/Cyanine5.5 anti-mouse F4/80 BM8 FC
Alexa Fluor® 700 anti-mouse F4/80 BM8 FC
Brilliant Violet 421™ anti-mouse F4/80 BM8 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse F4/80 BM8 FC
Alexa Fluor® 594 anti-mouse F4/80 BM8 IHC-F
Brilliant Violet 785™ anti-mouse F4/80 BM8 FC
Purified anti-mouse F4/80 (Maxpar® Ready) BM8 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse F4/80 BM8 FC
Brilliant Violet 650™ anti-mouse F4/80 BM8 FC
Brilliant Violet 711™ anti-mouse F4/80 BM8 FC
APC/Fire™ 750 anti-mouse F4/80 BM8 FC
TotalSeq™-A0114 anti-mouse F4/80 BM8 PG
TotalSeq™-B0114 anti-mouse F4/80 BM8 PG
TotalSeq™-C0114 anti-mouse F4/80 BM8 PG
Spark YG™ 570 anti-mouse F4/80 BM8 IHC-F
KIRAVIA Blue 520™ anti-mouse F4/80 BM8 FC
Ultra-LEAF™ Purified anti-mouse F4/80 BM8 FC,IHC,WB
APC/Fire™ 810 anti-mouse F4/80 BM8 FC
Spark NIR™ 685 anti-mouse F4/80 BM8 FC
Spark Blue™ 550 anti-mouse F4/80 BM8 FC
Brilliant Violet 570™ anti-mouse F4/80 BM8 FC
Brilliant Violet 750™ anti-mouse F4/80 BM8 FC
PE/Fire™ 810 anti-mouse F4/80 BM8 FC
Spark Red™ 718 anti-mouse F4/80 (Flexi-Fluor™) BM8 FC
Spark Blue™ 574 anti-mouse F4/80 (Flexi-Fluor™) BM8 FC
PE/Fire™ 640 anti-mouse F4/80 BM8 FC
PerCP/Fire™ 806 anti-mouse F4/80 BM8 FC
Go To Top Version: 4    Revision Date: 04/20/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account